Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoadjuvant Non-Small Cell Lung Cancer 1NSCLC 1Lung Neoplasms 1Adenocarcinoma of Lung 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Drug Therapy 7Carboplatin 7osimertinib 6Tomography, X-Ray Computed 5Pemetrexed 5Educational Status 5Interviews as Topic 4Early Intervention, Educational 4Cisplatin 4Blood Specimen Collection 4pembrolizumab 3cemiplimab 3atezolizumab 3Radiosurgery 3Methods 3Injections 3Etoposide 3durvalumab 2anlotinib 2aflutinib 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy 2Radiation 2PM 01183 2Observation 2Nivolumab 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lung Neoplasms × lorlatinib × Clear all
NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Hunan Cancer Hospital

Phase 2 Not yet recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡